CNN Shows Ted Cruz’s ‘Remarkable Flip-Flop’ On Donald Trump

Sen. Ted Cruz’s (R-Texas) “remarkable flip-flop” on Donald Trump is laid bare in a segment that aired on CNN’s “Outfront” on Monday.

CNN correspondent Tom Foreman examined Cruz’s astonishing about-turn on the outgoing president in the bit, noting how the Texas Republican has switched from calling Trump a “coward” and a “pathological liar” to backing the president’s desperate, lie-based bid to overturn the 2020 election.

Check out the segment here:

RELATED…

Stock Alert: Bed Bath & Beyond Climbs 5%

Shares of domestic merchandise retailer chain Bed Bath & Beyond Inc. (BBBY) are up more than 5% Tuesday morning at $19.02.

The company is scheduled to report its third quarter results on January 7, before the market opens.

On average, 16 analysts polled by Thomson Reuters expect the company to report earnings of $0.20 on revenue of $2.76 billion for the quarter.

BBBY has been trading in the range of $3.43- $26.16 in the last one year.

More than 20 killed in Mali airstrike on wedding ceremony – health worker

DAKAR (Reuters) – More than 20 people, including children, were killed in an airstrike during a wedding ceremony in central Mali on Sunday, a health worker with knowledge of the attack told Reuters.

Griffon Subsidiary AMES Buys Quatro Design For Undisclosed Financial Terms – Quick Facts

Griffon Corp. (GFF) said Tuesday that its subsidiary, AMES Companies, Inc., has acquired Quatro Design Pty Ltd. Financial terms of the transaction were not disclosed.

Quatro Design is an Australian manufacturer and supplier of glass fiber reinforced concrete landscaping products for residential, commercial, and public sector projects.

This acquisition, the sixth for AMES in Australia since 2013, further expands AMES’s product portfolio and sales channels in the Australian market.

Griffon expects Quatro to contribute about $5 million in annualized revenue and to be accretive to its earnings in the fiscal year ending September 30, 2021.

Herald morning quiz: January 6

Test your brains with the Herald’s morning quiz. Be sure to check back on nzherald.co.nz at 3pm for the afternoon quiz.

To challenge yourself with more quizzes, CLICK HERE.

Max Levchin's Affirm to raise up to $935 million in U.S. IPO

(Reuters) – Lending startup Affirm Holdings Inc, founded by PayPal Holdings Inc co-founder Max Levchin, aims to raise as much as $935 million in its initial public offering, it said in a filing on Tuesday.

Affirm, which will list its shares on Nasdaq, had planned to complete its IPO before the end of last year, but was forced to delay the share sale by a few weeks.

Several U.S. states sue regulator over 'true lender' rule

NEW YORK (Reuters) – Seven U.S. states and Washington, D.C. on Tuesday sued the U.S. Office of the Comptroller of the Currency, seeking to void a rule they said could encourage predatory lending by depriving them of their ability to enforce state laws against exploitative interest rates.

The complaint filed in Manhattan federal court seeks to set aside the “True Lender Rule,” which according to the states ran contrary to Congressional efforts to curtail the OCC’s ability to preempt state consumer protection laws.

Stock Alert: Cyclo Therapeutics Zooms 45%

Shares of clinical stage biotechnology company Cyclo Therapeutics, Inc. (CYTH) are surging more than 45% Tuesday morning following positive efficacy data from the study of long term safety and efficacy of its lead drug candidate Trappsol Cyclo in Niemann-Pick Disease Type C (NPC).

The company said, all eight patients included in the study demonstrated disease stability or improvement as measured by the 17-domain NPC Severity Score scale (NPC-SS), that calculates neurologic features of the disease, including ambulation, fine motor skills, ability to speak and swallow, and cognition.

Niemann-Pick disease, that affects the body’s ability to metabolize fat within cells, is characterized by progressive loss of function of nerves, the brain and other organs.

“These extension protocol data provide additional compelling support for the efficacy of our drug in this patient population, and as we launch our pivotal Phase 3 trial in early 2021,” said Cyclo Therapeutics CEO and Director, N. Scott Fine.

Cyclo Therapeutics has authorization from FDA to begin enrollment in its phase 3 trial and plans to enroll the first patient early in 2021.

CYTH is currently at $6.12. It has been trading in the range of 3.4- $33.5 in the past 52 weeks.

People Can’t Believe Donald Trump’s Latest Public Schedule Isn’t A Parody

President Donald Trump’s latest public schedule perplexed many people on Twitter Monday night.

The White House press office revealed that Trump would on Tuesday “work from early in the morning until late in the evening” and “make many calls and have many meetings.” Several journalists shared the statement on social media, including the BBC’s Jon Sopel:

The tone of the statement and its lack of details set Twitter alight.

Some critics likened it to something from a children’s book or North Korean propaganda. Others imagined what kind of calls Trump would make:

RELATED…